Photodynamic therapy of virus-associated epithelial tumours of the face in organ transplant recipients

Schleier, Peter; Hyckel, Peter; Berndt, Alexander; Bode, Hans-Peter; Albrecht, Volker; Hindermann, Winfried; Kosmehl, Hartwig; Zenk, W; Schumann, D.

doi:10.1007/s00432-003-0539-2

Cited by 25 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent short report found that MAL-PDT for NBCCS improves patient satisfaction and reduces the need for surgical procedures [130]. Topical PDT has been used to treat BCC in immunosuppressed patients with ALA-PDT clearing 30/32 facial tumours (including 21 BCC) in 5 OTR after one to three treatments [131]. PDT has also been assessed for its ability to prevent/delay new cancer development in OTR.…”

Section: Photodynamic Therapymentioning

confidence: 99%

Update of the European guidelines for basal cell carcinoma management

Trakatelli¹,

Morton²,

Nagore³

et al. 2014

European Journal of Dermatology

204

197

View full text Add to dashboard Cite

Background European guidelines for the management of basal cell carcinoma (BCC) prepared by the former BCC subcommittee of the Guidelines Committee of the European Dermatology Forum (EDF) were published in 2006. Objectives To present updated guidelines that include consensual expert definitions on various BCC types, prognosis and risk factors for BCC as well as review recommendations for diagnosis and treatment reflecting current published evidence. Methods These guidelines (S1 type) were prepared by the new BCC subgroup of the European Dermatology Forum (EDF)'s Guidelines Committee through extensive literature review (up to 2012) and expert experience; they were extensively discussed within the EDF subcommittee and approved by peer reviewers of the EDF. Results BCC is a common tumour with an incidence rising worldwide. Three major clinical types of BCC are recognized: nodular, superficial and morpheaform. Four histological subtypes are defined: superficial, nodular, infiltrative and morpheaform. On the basis of the risk of relapse, three prognosis groups have been identified: high, intermediate and low risk. According to these classifications and evidence-based evaluation of the therapeutic strategies available, a decision tree is proposed for the management of BCCs. Conclusions. The guidelines offer a useful tool that will help dermatologists to select the most appropriate treatment for individual patients.

show abstract

Section: Photodynamic Therapymentioning

confidence: 99%

Update of the European guidelines for basal cell carcinoma management

Trakatelli¹,

Morton²,

Nagore³

et al. 2014

European Journal of Dermatology

204

197

View full text Add to dashboard Cite

show abstract

“…In a randomized controlled trial, the same group reported an observed clearance of AK in 13 out of 17 OTRs at 16 weeks in areas treated by MAL-PDT (3 h; 600–730 nm; 75 J/cm 2 ; 80 mW/cm 2 ) [87]. Another group reported complete remission of 24 tumors (75%) in five OTRs with 32 facial tumors (21 BCC, eight AK, one keratoacanthoma and two SCC) following PDT (ALA: 3–5 h; 635 nm; 120 J/cm 2 ; 100 mW/cm 2 ) [88]. Two tumors, both SCC, were refractory to PDT.…”

Section: Clinical Applications Of Pdt For Cutaneous Neoplasiamentioning

confidence: 99%

Recent advances in the prevention and treatment of skin cancer using photodynamic therapy

Zhao¹,

He²

2010

Expert Review of Anticancer Therapy

140

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a noninvasive procedure that involves a photosensitizing drug and its subsequent activation by light to produce reactive oxygen species that specifically destroy target cells. Recently, PDT has been widely used in treating non-melanoma skin malignancies, the most common cancer in the USA, with superior cosmetic outcomes compared with conventional therapies. The topical 'photosensitizers' commonly used are 5-aminolevulinic acid (ALA) and its esterified derivative methyl 5-aminolevulinate, which are precursors of the endogenous photosensitizer protoporphyrin IX. After treatment with ALA or methyl 5-aminolevulinate, protoporphyrin IX preferentially accumulates in the lesion area of various skin diseases, which allows not only PDT treatment but also fluorescence diagnosis with ALA-induced porphyrins. Susceptible lesions include various forms of non-melanoma skin cancer such as actinic keratosis, basal cell carcinoma and squamous cell carcinoma. The most recent and promising developments in PDT include the discovery of new photosensitizers, the exploitation of new drug delivery systems and the combination of other modalities, which will all contribute to increasing PDT therapeutic efficacy and improving outcome. This article summarizes the main principles of PDT and its current clinical use in the management of non-melanoma skin cancers, as well as recent developments and possible future research directions.Keywords 5-aminolevulinic acid; ALA; MAL; methyl 5-aminolevulinate; PDT; photodynamic therapy; photosensitizers; skin cancer; topical PDT Skin cancer is the most common form of cancer, accounting for nearly half of all cancers in the USA [1]. The most common types of skin cancer are non-melanoma skin cancers (NMSCs): basal cell carcinoma (BCC), which forms in the basal cells, and squamous cell carcinoma (SCC), which forms in the squamous cells. BCCs are rarely fatal, but can be † Author for correspondence: Tel.: +1 773 795 4696, Fax: +1 773 702 8398, yyhe@medicine.bsd.uchicago.edu. Financial & competing interests disclosureWork in the authors' laboratories was supported by the American Skin Association, the University of Chicago Cancer Research Center (P30 CA014599), and the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript. NIH Public Access Author ManuscriptExpert Rev Anticancer Ther. Author manuscript; available in PMC 2011 September 1. Genetic factors and environmental exposure to UV radiation in sunlight or tanning beds are strong risk factors for the genesis of skin cancer. Traditional skin c...

show abstract

“…Although the number of reported studies so far is small, PDT in OTRs appears to be more effective for BCC than AK with remission rates of 75% after 12 weeks, compared to 48% in AK [60], and a low recurrence rate of under 6% after 22 months of followup [43, 61]. …”

Section: Photodynamic Therapymentioning

confidence: 99%

Use of Photodynamic Therapy for Treatment of Actinic Keratoses in Organ Transplant Recipients

Wlodek

Ali

Lear

2013

BioMed Research International

View full text Add to dashboard Cite

Solid organ transplant recipients are predisposed to actinic keratoses (AK) and nonmelanoma skin cancers, owing to the lifelong immunosuppression required. Today, increasing numbers of organ transplants are being performed and organ transplant recipients (OTRs) are surviving much longer. Photodynamic therapy (PDT) is proving a highly effective treatment modality for AK amongst this susceptible group of patients. Following an overview of the pathogenesis of AK amongst OTRs, the authors review current safety and efficacy data and how this relates to the role of PDT for the treatment of AK in OTRs.

show abstract

Photodynamic therapy of virus-associated epithelial tumours of the face in organ transplant recipients

Cited by 25 publications

References 33 publications

Update of the European guidelines for basal cell carcinoma management

Update of the European guidelines for basal cell carcinoma management

Recent advances in the prevention and treatment of skin cancer using photodynamic therapy

Use of Photodynamic Therapy for Treatment of Actinic Keratoses in Organ Transplant Recipients

Contact Info

Product

Resources

About